Virax Biolabs Group Ltd annual report, Q4 FY2023

Virax Biolabs Group Limited — Form 20-F Summary

Reporting period: Fiscal year ended March 31, 2023, compared with fiscal 2022. Although the request refers to “2022 Q4,” this filing is an annual report, not a quarterly filing. The financial statements were prepared under IFRS as issued by the IASB and received an unmodified audit opinion for fiscal 2023.

Business context

Virax is a development-stage biotechnology and diagnostics company. It distributes third-party diagnostic test kits through ViraxClear and is developing ViraxImmune, a proprietary T-cell immune-response testing platform and related mobile application. ViraxClear generated all reported revenue; ViraxImmune had not been submitted for regulatory approval by the report date.

Key financial metrics

• Research and development expense was $397,109, down from $433,743. General and administrative expense rose to $5,307,671 from $1,286,118, principally reflecting IPO and public-company costs, hiring, salaries and benefits, stock-based compensation, and directors’ and officers’ insurance.
• Other income was $274,998, including a $294,383 gain on extinguishment of a vendor debt; interest expense was $15,468. The debt-extinguishment gain reduced the reported net loss.
• At March 31, 2023, total assets were $9,812,416, current liabilities were $908,401, and total equity was $8,904,015. Current liabilities included a $146,250 note payable and $38,250 of deferred revenue. The note financed D&O insurance and bore 2.5% fixed interest.
• Investing cash outflow was $178,403, for capitalized software costs. Financing provided $13,688,952, primarily from the IPO and private placements. The company reported an accumulated deficit of $11,794,460.

Changes, outlook and risks

• Revenue was minimal and concentrated: one customer accounted for 100% of fiscal 2023 sales; five customers accounted for 100% in fiscal 2022. The 2023 sale generated a gross loss.
• The company completed its July 2022 IPO, reporting approximately $7.05 million in net proceeds, and private placements in November 2022 and March 2023. The March placement included shares, pre-funded warrants and investment options. Management said available cash was expected to fund its plan and working capital through 2023, but additional capital would be required over the longer term; it did not provide a forecast of revenue or profitability.
• Management expected to submit the ViraxImmune T-cell test for regulatory review in the second half of 2023 and described clinical trials planned for Q3 2023. These were forward-looking plans, not approvals or demonstrated commercial outcomes. The filing also describes North American market expansion plans, with timing varying by passage.
• ViraxImmune’s prototype and clinical evidence remained under development. Key risks include clinical validation and regulatory approval, commercialization and market acceptance, dependence on a few customers and suppliers, continued losses and financing needs, competition, data privacy and cybersecurity, and regulatory and political uncertainty relating to China and Hong Kong.
• Management stated that disclosure controls and internal control over financial reporting were effective as of March 31, 2023; the auditor did not attest to internal-control effectiveness. The prior-year audit report included a going-concern paragraph; the FY2023 filing says financing alleviated that concern, while also warning that future funding will be needed.
• Potential dilution is material: 9,953,062 warrants were reported outstanding at year-end and 1,212,000 stock options were outstanding, with none exercisable at that date. The filing reports 15,547,089 shares outstanding at March 31, 2023 and 17,890,398 as of the report date.

Important facts for investors to verify

1. Check subsequent regulatory filings and announcements for ViraxImmune clinical-trial progress, regulatory submissions, clearances, and actual launch timing.
2. Reconcile share counts and warrant exercises after year-end. The subsequent-events note says 2,343,309 pre-funded warrants were exercised but also states 2,303,309 shares were issued.
3. Review subsequent cash use, financing needs, and the company’s actual runway against management’s expectation that cash would support operations through 2023.
4. Assess the sustainability and economics of ViraxClear revenue given the very small sales base, negative gross profit, and customer concentration.
5. Confirm the potential dilution and terms of outstanding warrants, investment options, and equity awards, and track how financing proceeds are used.